ANIXClinical Trials•prnewswire•August 18, 2025 at 01:00 PM

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Sentiment:Positive (70)

Summary

Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif., Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 18, 2025 by prnewswire